Diabetes

February 22, 2019
Published by admin_auro at February 22, 2019
Categories

Ribonucleic acid-based therapy for glucose homeostasis and TIIDM:  LncRNA PCGEM1 increases Pax6 and insulin expression, decreases the levels of glucagon, ghrelin and Somatostatin, reduces metabolic stress, improves insulin sensitivity, promotes glucose homeostasis and prevents progression to TIIDM, via down regulation of its target gene, 22/February/2019, 11.35 pm

Introduction: What they say A study from the Department of Developmental Biology and Cancer Research, The Institute for Medical Research Israel-Canada, The Hebrew University-Hadassah Medical School, […]
Do you like it?0
Read more
February 22, 2019
Published by admin_auro at February 22, 2019
Categories

Molecular therapy for diabetes: Teneligliptin (brand name: Tenilia), a DPP-4 (a dipeptidyl peptidase-4) inhibitor used in the treatment of hyperglycemia,  increases the expression of IGF1R, INSR, and IRS2, and promotes an insulin-sensitized state, via up-regulation of  its target gene Lin28, 22/February/2019, 10.22 pm

 Introduction: What they say:   A study from the Stem Cell Transplantation Program, Division of Pediatric Hematology/Oncology, Boston Children’s Hospital and Dana-Farber Cancer Institute, Boston, Massachusetts, USA shows that “The Lin28/let-7 axis […]
Do you like it?0
Read more
February 22, 2019
Published by admin_auro at February 22, 2019
Categories

Ribonucleic acid-based therapy for diabetes: LncRNA UCA1  increases the expression of IGF1R, INSR, and IRS2, and promotes an insulin-sensitized state, via up-regulation of  its target gene Lin28, 22/February/2019, 9.32 pm

 Introduction: What they say:   A study from the Stem Cell Transplantation Program, Division of Pediatric Hematology/Oncology, Boston Children’s Hospital and Dana-Farber Cancer Institute, Boston, Massachusetts, USA shows that “The Lin28/let-7 axis […]
Do you like it?0
Read more
February 18, 2019
Published by admin_auro at February 18, 2019
Categories

Molecular therapy for Diabetes Mellitus: Dapagliflozin (trade name: Forxiga, & Farxiga), a sodium glucose cotransporter-2 inhibitor used in the treatment of TIIDM, augments the expression of FGF19 and FGF1,  attenuates hepatic glucose production, decreases hepatic acetyl CoA content, brings down the levels of plasma ACTH, and corticosterone, augments insulin sensitivity, promotes weight loss and alleviates TIDM via upregulation of its target gene, 18/February/2019, 2.57 pm

Introduction: What they say  A study from Diabetes and Obesity Center of Excellence, Department of Medicine, University of Washington, Seattle, Washington, USA shows that Central injection […]
Do you like it?0
Read more
1234567891011121314151617181920212223242526272829303132333435363738394041424344454647484950515253545556575859606162636465666768697071727374757677787980818283848586878889909192939495
Next page